Esperion Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
Esperion (NASDAQ: ESPR) announced on August 7, 2024, the granting of 66,800 restricted stock units (RSUs) to 18 new employees under its 2017 Inducement Equity Incentive Plan. This plan is exclusively used for equity awards to individuals who were not previously employees or non-employee directors of Esperion, as an inducement for employment.
The RSUs will vest over four years, with 25% vesting on the one-year anniversary of the recipient's vesting commencement date, and the remaining 75% vesting in twelve equal quarterly installments thereafter. Vesting is subject to continued employment with Esperion. The RSUs are governed by the terms and conditions of Esperion's 2017 Inducement Equity Incentive Plan and the RSU agreement covering the grant.
Esperion (NASDAQ: ESPR) ha annunciato il 7 agosto 2024, l'assegnazione di 66.800 unità azionarie vincolate (RSU) a 18 nuovi dipendenti nell'ambito del suo Piano di Incentivazione Azionaria del 2017. Questo piano è utilizzato esclusivamente per attribuzioni azionarie a individui che non erano precedentemente dipendenti o direttori non dipendenti di Esperion, come incentivo per l'assunzione.
Le RSU si matureranno in quattro anni, con il 25% che maturerà nel primo anniversario della data di inizio del maturamento del destinatario, e il restante 75% che maturerà in dodici rate trimestrali uguali. La maturazione è soggetta al mantenimento dell'impiego presso Esperion. Le RSU sono regolate dai termini e dalle condizioni del Piano di Incentivazione Azionaria del 2017 di Esperion e dall'accordo RSU relativo all'assegnazione.
Esperion (NASDAQ: ESPR) anunció el 7 de agosto de 2024, la concesión de 66,800 unidades de acciones restringidas (RSU) a 18 nuevos empleados bajo su Plan de Incentivos de Capital de 2017. Este plan se utiliza exclusivamente para otorgar acciones a individuos que no eran anteriormente empleados o directores no empleados de Esperion, como un incentivo para el empleo.
Las RSU se consolidarán en un periodo de cuatro años, con un 25% que se consolidará en el primer aniversario de la fecha de inicio de consolidación del destinatario, y el 75% restante que se consolidará en doce cuotas trimestrales iguales a partir de entonces. La consolidación está sujeta a la continuación del empleo en Esperion. Las RSU están regidas por los términos y condiciones del Plan de Incentivos de Capital de 2017 de Esperion y el acuerdo de RSU que cubre la concesión.
Esperion (NASDAQ: ESPR)는 2024년 8월 7일, 2017 유인 자본 인센티브 계획에 따라 18명의 신규 직원에게 66,800개의 제한 주식 단위(RSU)를 부여했다고 발표했습니다. 이 계획은 이전에 Esperion의 직원이나 비직원 이사가 아닌 개인에게 주식 보상을 제공하기 위해 독점적으로 사용됩니다.
RSU는 4년에 걸쳐 완전히 부여되며, 수령자의 완전 부여 시작일의 1주년 기념일에 25%가 부여되고, 나머지 75%는 그 이후 매 분기 12회에 걸쳐 동등한 분할 방식으로 부여됩니다. 부여는 Esperion에서 계속 고용되는 조건으로 제한됩니다. RSU는 Esperion의 2017 유인 자본 인센티브 계획과 관련된 RSU 계약의 조건에 따라 관리됩니다.
Esperion (NASDAQ: ESPR) a annoncé le 7 août 2024, l'attribution de 66 800 unités d'actions restreintes (RSU) à 18 nouveaux employés dans le cadre de son Plan d'Incentive en Actions de 2017. Ce plan est exclusivement utilisé pour attribuer des actions à des individus qui n'étaient pas auparavant employés ou directeurs non-salariés d'Esperion, comme incitation à l'embauche.
Les RSU se verront attribuer des droits sur une période de quatre ans, avec 25 % des droits qui se libéreront à la première date d'anniversaire du début de la période d'acquisition du bénéficiaire, et les 75 % restants qui se libéreront en douze versements trimestriels égaux par la suite. L'attribution des droits est soumise à la poursuite de l'emploi chez Esperion. Les RSU sont régies par les termes et conditions du Plan d'Incentive en Actions de 2017 d'Esperion et par le contrat de RSU couvrant l'attribution.
Esperion (NASDAQ: ESPR) gab am 7. August 2024 bekannt, dass 66.800 eingeschränkte Aktieneinheiten (RSUs) an 18 neue Mitarbeiter im Rahmen seines Kapitalanreizplans von 2017 gewährt wurden. Dieser Plan wird ausschließlich für eigenkapitalbasierte Vergütungen an Personen verwendet, die zuvor keine Mitarbeiter oder nicht-angestellte Direktoren von Esperion waren, als Anreiz für die Beschäftigung.
Die RSUs werden über einen Zeitraum von vier Jahren verfallen, wobei 25 % am ersten Jahrestag des Beginns der Vesting-Periode des Empfängers verfallen und die verbleibenden 75 % danach in zwölf gleichen vierteljährlichen Raten verfallen. Der Vesting ist an die fortdauernde Beschäftigung bei Esperion gebunden. Die RSUs unterliegen den Bedingungen des Kapitalanreizplans von 2017 von Esperion und dem RSU-Vertrag, der die Zuteilung abdeckt.
- Esperion is attracting new talent with equity incentives
- The company is expanding its workforce with 18 new employees
- Potential dilution of existing shareholders due to new RSU grants
ANN ARBOR, Mich., Aug. 07, 2024 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced that on August 7, 2024, the Company granted 18 new employees 66,800 restricted stock units (RSUs) under Esperion’s 2017 Inducement Equity Incentive Plan.
The 2017 Inducement Equity Incentive Plan is used exclusively for the grant of equity awards to individuals who were not previously an employee or non-employee director of Esperion (or following a bona fide period of non-employment), as an inducement material to such individual's entering into employment with Esperion, pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules.
Each RSU will vest and become exercisable as to 25 percent of the shares on the one-year anniversary of the recipient’s vesting commencement date and will vest and become exercisable as to the remaining 75 percent of the shares in twelve equal quarterly installments at the end of each quarter following such anniversary, in each case, subject to each such employee's continued employment with Esperion on such vesting dates. The RSUs are subject to the terms and conditions of Esperion’s 2017 Inducement Equity Incentive Plan, and the terms and conditions of the RSU agreement covering the grant.
Esperion Therapeutics
At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases. The status quo is not meeting the health needs of millions of people with high cholesterol – that is why our team of passionate industry leaders is breaking through the barriers that prevent patients from reaching their goals. Providers are moving toward reducing LDL-cholesterol levels as low as possible, as soon as possible; we provide the next steps to help get patients there. Because when it comes to high cholesterol, getting to goal is not optional. It is our life’s work. For more information, visit esperion.com and esperionscience.com and follow us on Twitter at twitter.com/EsperionInc.
Esperion Contact Information:
Investors:
Alina Venezia
investorrelations@esperion.com
(734) 887-3903
Media:
Tiffany Aldrich
corporateteam@esperion.com
(616) 443-8438
FAQ
How many restricted stock units (RSUs) did Esperion (ESPR) grant on August 7, 2024?
What is the vesting schedule for the RSUs granted by Esperion (ESPR)?
Under which plan did Esperion (ESPR) grant the new RSUs?
What is the purpose of Esperion's (ESPR) 2017 Inducement Equity Incentive Plan?
